Juan Madoz-Gurpide
Overview
Explore the profile of Juan Madoz-Gurpide including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
993
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Madoz-Gurpide J, Serrano-Lopez J, Sanz-Alvarez M, Morales-Gallego M, Rodriguez-Pinilla S, Rovira A, et al.
Int J Mol Sci
. 2025 Feb;
26(4).
PMID: 40004024
HER2 (human epidermal growth factor receptor 2) is overexpressed in approximately 15-20% of breast cancers, leading to aggressive tumour growth and poor prognosis. Anti-HER2 therapies, such as trastuzumab and pertuzumab,...
2.
Sanz-Alvarez M, Luque M, Morales-Gallego M, Cristobal I, Ramirez-Merino N, Rangel Y, et al.
Int J Mol Sci
. 2024 Jan;
25(1).
PMID: 38203378
The combination of trastuzumab and pertuzumab as first-line therapy in patients with HER2-positive breast cancer has shown significant clinical benefits compared to trastuzumab alone. However, despite initial therapeutic success, most...
3.
Santos A, Cristobal I, Carames C, Luque M, Sanz-Alvarez M, Madoz-Gurpide J, et al.
Int J Mol Sci
. 2023 May;
24(9).
PMID: 37175484
MicroRNA (miR)-19b is deregulated in colorectal cancer (CRC) and locally advanced rectal cancer (LARC), predicting worse outcome and disease progression in CRC patients, and acting as a promising prognostic marker...
4.
Cabello P, Torres-Ruiz S, Adam-Artigues A, Fores-Martos J, Martinez M, Hernando C, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046799
Trastuzumab treatment has significantly improved the prognosis of HER2-positive breast cancer patients. Despite this, resistance to therapy still remains the main clinical challenge. In order to evaluate the implication of...
5.
Torres-Ruiz S, Tormo E, Garrido-Cano I, Lameirinhas A, Rojo F, Madoz-Gurpide J, et al.
Int J Mol Sci
. 2023 Feb;
24(4).
PMID: 36835014
Due to the lack of specific targets, cytotoxic chemotherapy still represents the common standard treatment for triple-negative breast patients. Despite the harmful effect of chemotherapy on tumor cells, there is...
6.
Luque M, Sanz-Alvarez M, Morales-Gallego M, Madoz-Gurpide J, Zazo S, Dominguez C, et al.
Cancers (Basel)
. 2022 Dec;
14(24).
PMID: 36551522
Human epidermal growth factor receptor 2-positive (HER2-positive) breast cancer accounts for 15 to 25% of breast cancer cases. Although therapies based on the use of monoclonal anti-HER2 antibodies present clinical...
7.
Santos A, Cristobal I, Rubio J, Carames C, Luque M, Sanz-Alvarez M, et al.
Int J Mol Sci
. 2022 Oct;
23(20).
PMID: 36293302
The standard clinical management of locally advanced rectal cancer (LARC) patients includes neoadjuvant 5-fluorouracil (5-FU)-based chemoradiotherapy (CRT) followed by mesorectal excision. MicroRNA (miR)-19b expression levels in LARC biopsies obtained from...
8.
Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez J, Candela-Noguera V, Rojo F, et al.
Cancer Commun (Lond)
. 2022 Aug;
42(12):1412-1416.
PMID: 35997029
No abstract available.
9.
Luque M, Cristobal I, Sanz-Alvarez M, Santos A, Zazo S, Eroles P, et al.
J Clin Med
. 2022 Mar;
11(6).
PMID: 35329936
Together with its reported ability to modulate AKT phosphorylation (p-AKT) status in several tumor types, the oncoprotein CIP2A has been described to induce breast cancer progression and drug resistance. However,...
10.
Santos A, Cristobal I, Rubio J, Carames C, Luque M, Sanz-Alvarez M, et al.
Int J Mol Sci
. 2022 Feb;
23(4).
PMID: 35216319
The identification of robust prognostic markers still represents a need in locally advanced rectal cancer (LARC). MicroRNAs (miRs) have progressively emerged as promising circulating markers, overcoming some limitations that traditional...